Table 1 Clinical trials of conventional drugs in combination therapy against cancer
From: The updated landscape of tumor microenvironment and drug repurposing
Conventional Drug | Combination Therapy | Targeting Cancer | ClinicalTrials.gov Identifier | Recruitment Status |
|---|---|---|---|---|
Aspirin | Immunotherapy (atezolizumab, bevacizumab, pembrolizumab, avelumab, nivolumab, ipilimumab, lenalidomide) | Ovarian cancer, HNSCC, TNBC, solid adult tumor, multiple myeloma | NCT04188119 | Not yet recruiting |
NCT02659384; NCT03245489; NCT03728179; NCT03428373 | Recruiting | |||
Combination immunomodulatory cocktail (Vitamin D, aspirin, CTX and lansoprazole), pembrolizumab, radiation and curcumin | Cervical cancer, endometrial cancer, uterine cancer | NCT03192059 | Recruiting | |
Targeted therapy (osimertinib) | NSCLC | NCT03532698; NCT03543683; NCT04184921 | Not yet recruiting | |
Celecoxib | Immunotherapy (nivolumab) | Metastatic cancer | NCT03864575 | Not yet recruiting |
Targeted therapy (erlotinib, toripalimab, cetuximab, gefitinib, carboplatin, exemestane, depsipeptide) | Squamous cell carcinoma of oral cavity, colorectal cancer, breast cancer, NSCLC, HNSCC, ovarian cancer, pulmonary and pleural malignancies | NCT02748707 | Active, not recruiting | |
NCT03926338 | Recruiting | |||
NCT00466505; NCT00068653; NCT00400374; NCT00072072; NCT00062101; NCT00499655; NCT01124435; NCT00201773; NCT00037817 | Completed | |||
Chemotherapy (cisplatin, gemcitabine, docetaxel, paclitaxel and carboplatin, etoposide, irinotecan, capecitabine CTX, methotrexate, docetaxel, fluorouracil, vinblastine, 6-TG, temozolomide, CCNU, decitabine, DFMO, topotecan) | Pancreatic cancer, NSCLC, bladder cancer, TNBC, GBM, advanced cancer, colorectal cancer, cholangiocarcinoma, sarcoma, pulmonary and pleural malignancies, neuroblastoma, relapsed or progressive cancer | NCT02770378; NCT02030964 | Active, not recruiting | |
NCT02885974; NCT04081389; NCT03498326 | Recruiting | |||
NCT00176813; NCT00030407; NCT00030420; NCT00062179; NCT00551005; NCT00101686; NCT00084721; NCT00551889; NCT02280694; NCT00320918; NCT00073866; NCT00064181; NCT00230399; NCT00085163; NCT00061893; NCT00047281; NCT00504660; NCT00037817; NCT00165451 | Completed | |||
Radiation therapy | NSCLC | NCT00046839 | Completed | |
Targeted therapy and chemotherapy | Recurrent and/or refractory solid and CNS tumors | NCT02574728 | Recruiting | |
Chemoradiotherapy | Rectal cancer, cervix neoplasms, GBM, NSCLC, operable esophageal cancer | NCT00931203; NCT00336960; NCT00152828; NCT00112502; NCT00188565; NCT00346801; NCT00137852 | Completed | |
DC Vaccine, IFN alpha-2 and rintatolimod | Melanoma, peritoneal surface malignancies | NCT04093323 | Not yet recruiting | |
NCT02151448 | Completed | |||
DC vaccine and cisplatin | Ovarian cancer | NCT02432378 | Recruiting | |
Gemcitabine and gene therapy (rAd-IFN) | Malignant pleural mesothelioma | NCT03710876 | Recruiting | |
Chemotherapy (carboplatin, gemcitabine) and 5-LOX inhibitor zileuton | Advanced NSCLC | NCT00070486 | Completed | |
Etoposide, CTX, thalidomide, fenofibrate | Relapsed or progressive cancer | NCT00357500 | Completed | |
ARTA and itraconazole | Multiple myeloma | NCT02401295 | Completed | |
β-blocker | Immunotherapy (pembrolizumab) | Cutaneous melanoma | NCT03384836 | Recruiting |
Chemotherapy (doxorubicin, vinorelbine, paclitaxel, nab-paclitaxel, doxorubicin, CTX) | EOC, primary peritoneal carcinoma, fallopian tube cancer, breast cancer, gastric cancer, Malignant soft tissue sarcoma, pediatric cancer | NCT02897986 | Not yet recruiting | |
NCT01847001 | Active, not recruiting | |||
NCT04005365; NCT03108300 | Recruiting | |||
NCT01308944 | Completed | |||
NASIDs (etodolac) | Colorectal cancers; Pancreatic cancer | NCT03919461; NCT03838029 | Recruiting | |
Prednisone | Hemangioma | NCT01072045 | Completed | |
Relaxation/guided imagery audio intervention | Cervical cancer | NCT01902966 | Active, not recruiting | |
Metformin | Immunotherapy (nivolumab, pembrolizumab, sintilimab) | NSCLC, SCLC, melanoma, solid tumors | NCT03048500; NCT03311308; NCT03874000; NCT03874000 | Recruiting |
NCT02145559 | Completed | |||
Targeted therapy (temsirolimus, vandetanib, sirolimus, lapatinib, erlotinib, irinotecan, gefitinib, sapanisertib, dabrafenib, trametinib, ritonavir, nelfinavir, toremifene, everolimus, letrozole, lanreotide) | Advanced cancers, kidney cancer, TNBC, colorectal cancer, NSCLC, advanced or metastatic relapsed or refractory cancers, lymphoma, melanoma, multiple myeloma or chronic lymphocytic leukemia, breast cancer, endometrial carcinoma, neuroendocrine tumors | NCT01529593; NCT02948283; NCT01797523 | Active, not recruiting | |
NCT01930864; NCT03017833; NCT02143050; NCT03829020; NCT02506790; NCT02823691 | Recruiting | |||
NCT02495103; NCT01087983; NCT01650506; NCT01864681; NCT00659568 | Completed | |||
Chemotherapy (docetaxel, carboplatin, paclitaxel, oxaliplatin, gemcitabine, vincristine, irinotecan, temozolomide, CTX, myocet, VPLD, R-CHOP, FDC) | Ovarian cancer, fallopian tube cancer, primary peritoneal cancer; esophageal squamous cell carcinoma, prostate cancer, pancreatic cancer, breast cancer, glioblastoma, pediatric tumor, childhood ALL, diffuse large-B-cell lymphoma | NCT03833466 | Not yet recruiting | |
NCT02336087; NCT01528046; NCT03200015 | Active, not recruiting | |||
NCT02437812; NCT02122185; NCT04170465; NCT01929811; NCT03243851; NCT02506777 | Recruiting | |||
NCT01796028; NCT01210911; NCT02312661; NCT02005419; NCT01666730; NCT01971034; NCT01442870; NCT01885013; NCT01324180 | Completed | |||
Chemoradiotherapy | Cervix cancer, lung cancer, HNSCC, rectal cancer | NCT02115464; NCT02325401; NCT01430351 | Active, not recruiting | |
NCT02394652; NCT02949700 | Recruiting | |||
NCT02437656 | Completed | |||
Chemotherapy and targeted therapy | Endometrial cancer | NCT02755844 | Active, not recruiting | |
Antiandrogen (enzalutamide, bicalutamide) | Prostate cancer | NCT02339168 | Active, not recruiting | |
NCT02640534; NCT02614859 | Recruiting | |||
Antibiotic (doxycycline) | Breast cancer, uterine cancer, HNSCC | NCT03076281 | Active, not recruiting | |
NCT02874430 | Recruiting | |||
Chloroquine | IDH1/2-mutated solid tumors | NCT02496741 | Completed | |
Omega-3 fatty acids | Early stage breast cancer | NCT02278965 | Active, not recruiting | |
Vitamin C | Hepatocellular cancer, pancreatic cancer, gastric cancer, colorectal cancer | NCT04033107 | Recruiting | |
Statin | Targeted therapy (sorafenib, erlotinib, anti-HER2 therapy, fulvestrant, aromatase Inhibitors) | hepatocellular carcinoma, squamous cell carcinoma, NSCLC, breast cancer | NCT03275376; NCT03324425; NCT02958852 | Recruiting |
NCT00966472 | Completed | |||
Chemotherapy (capecitabine, topotecan, CTX, zoledronate, bortezomib, bendamustin) | Rectal cancer, multiple myeloma, pediatric solid and CNS tumors, TNBC | NCT02569645; NCT02390843; NCT03358017 | Recruiting | |
NCT02161822; NCT00399867 | Completed | |||
Chemoradiotherapy | GBM | NCT02029573 | Completed | |
Digoxin and enzalutamide | Prostate cancer | NCT04094519 | Recruiting | |
Ezetimibe | Prostate cancer | NCT02534376 | Completed | |
Combination | Combination statin and celecoxib | Optico-chiasmatic gliomas | NCT02115074 | Active, not recruiting |
Combination celecoxib, β-blocker, CTX, etoposide and vinblastin | Neuroblastoma | NCT02641314 | Recruiting | |
Combination aspirin, celecoxib and PD-1 antibody BAT1306 | Colorectal cancer | NCT03638297 | Recruiting | |
Combination metformin and statin | Breast cancer | NCT01980823 | Recruiting | |
Combination statin, aspirin and dutasteride | Prostate cancer | NCT01428869 | Completed |
